<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873327</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00020476</org_study_id>
    <nct_id>NCT00873327</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates</brief_title>
  <official_title>Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phillip Brian Smith</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety&#xD;
      of piperacillin-tazobactam in infants &lt; 61 days of age with suspected sepsis. There will be&#xD;
      four cohorts of 8 infants each:&#xD;
&#xD;
        1. &lt; 32 weeks gestational age (GA) and &lt; 14 days postnatal age (PNA)&#xD;
&#xD;
        2. &lt; 32 weeks gestational age and &gt;=14 days postnatal age&#xD;
&#xD;
        3. &gt;=32 weeks gestational age and &lt; 14 days postnatal age&#xD;
&#xD;
        4. &gt;=32 weeks gestational age and &gt;=14 days postnatal age. The study requires&#xD;
           administration of 6 doses of study drug along with other antimicrobials per standard of&#xD;
           care followed by 1 week of safety monitoring. Four 200 µL pK samples will be obtained at&#xD;
           steady state. The risks are reasonable vs. the benefits and have been minimized&#xD;
           appropriately. There may be benefit to the subjects (administration of broad spectrum&#xD;
           empirical antimicrobial therapy), and information from the study may benefit a large&#xD;
           number of other infants in whom the drug is currently being administered despite the&#xD;
           lack of PK data in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedures Prior to Receipt of First Dose of Study Drug&#xD;
&#xD;
      Parental/Guardian Permission Prior to the start of any study-related procedure, a signed and&#xD;
      dated informed consent and HIPAA authorization must be obtained and documented in the&#xD;
      infant's medical record. Once it has been determined that the infant meets all inclusion&#xD;
      criteria and no exclusion criteria, the infant will be assigned a subject identification&#xD;
      number that will be used on the subject's CRFs and will be considered enrolled.&#xD;
&#xD;
      Study Drug Administration&#xD;
&#xD;
      Assignment to Therapy Groups Infants meeting the eligibility will receive&#xD;
      piperacillin-tazobactam. Concomitant use of an aminoglycoside is suggested. Enrollment and&#xD;
      study drug dose will be stratified by GA and PNA. After enrollment information for the&#xD;
      eligible infant is provided, the dosage assignment and subject number will be allocated. If&#xD;
      an infant is assigned a study drug and a number, but does not receive study drug, the subject&#xD;
      number will not be used again. The reason for not dosing the subject will be noted on the&#xD;
      case report form (CRF).&#xD;
&#xD;
      Dosing:&#xD;
&#xD;
      Infants &lt;32 weeks gestation at birth&#xD;
&#xD;
      &lt; 14 days PNA 100 mg/kg Q8&#xD;
&#xD;
      &gt;=14 weeks PNA 100 mg/kg Q6&#xD;
&#xD;
      Infants ≥32 weeks gestation at birth&#xD;
&#xD;
      &lt; 14 days PNA 100 mg/kg Q6&#xD;
&#xD;
      &gt;=14 days PNA 100 mg/kg Q6&#xD;
&#xD;
      Dispensing of Study Drug The pharmacist at each site will prepare and dispense the study&#xD;
      drug. Study drug will be dispensed by the pharmacy in appropriate size syringes and&#xD;
      administered via a syringe pump at a rate calculated based on the infants' body weight in&#xD;
      kilograms (kg) per local standard of care, but with a target of infusing the product over 30&#xD;
      minutes. Immediately following study drug administration the infusion tubing will be flushed&#xD;
      per the unit protocol.&#xD;
&#xD;
      Piperacillin-tazobactam should not be mixed with or physically added to solutions containing&#xD;
      other drugs. Infusion vials of piperacillin-tazobactam will be reconstituted and stored per&#xD;
      the package insert and local pharmacy requirements. Parenteral drug products should be&#xD;
      inspected visually for particulate matter and discoloration prior to administration, whenever&#xD;
      solution and container permit.&#xD;
&#xD;
      Dosing for infants receiving piperacillin-tazobactam per local standard of care Once an&#xD;
      infant is enrolled in the study, steady state PK levels may be drawn after the 4th, 5th, or&#xD;
      6th dose of piperacillin-tazobactam. These doses may include both pre-study doses of&#xD;
      piperacillin-tazobactam and post-consent, 'on-study', doses if the dosage and dosing interval&#xD;
      of piperacillin-tazobactam remains the same. If a subject receives &lt; 4 doses of on-study&#xD;
      piperacillin-tazobactam at the time of steady state PK sampling, ≥ 4 doses (pre-study doses +&#xD;
      on study doses) of piperacillin-tazobactam should be recorded on the Study Drug&#xD;
      Administration CRF.&#xD;
&#xD;
      Other antimicrobial treatments Investigators are encouraged to provide infants with&#xD;
      concomitant aminoglycoside therapy. Use of other antimicrobial agents (vancomycin,&#xD;
      antifungals) may be given per local standard of care. A maximum of 6 doses of on study&#xD;
      piperacillin-tazobactam will be administered under this protocol. Additional doses&#xD;
      piperacillin-tazobactam or other antimicrobials may be administered per standard of care but&#xD;
      will not be recorded on study CRFs.&#xD;
&#xD;
      Procedures by Visit&#xD;
&#xD;
      Pre-Study Drug Administration Procedures (Study Day 0)&#xD;
&#xD;
      The following procedures will be completed prior to the administration of study drug:&#xD;
&#xD;
      a. Review of Inclusion/Exclusion Criteria prior to infant enrollment b. Obtain signed and&#xD;
      dated informed consent/HIPAA consent. c. Collect demographic data and medical history d.&#xD;
      Perform a complete physical examination e. Obtain and record infant weight and medication&#xD;
      dosing weight for calculation of appropriate study drug dose if different from actual weight&#xD;
      f. Record results from hematology and serum chemistry labs if obtained within 72 hours prior&#xD;
      to enrollment in accordance with local standard of care. Use the laboratory values closest to&#xD;
      enrollment if there have been multiple tests.&#xD;
&#xD;
        1. Hematology labs will include: hematocrit, hemoglobin, white blood cell count with&#xD;
           differential, and platelet count.&#xD;
&#xD;
        2. Serum chemistry will include glucose, creatinine, blood urea nitrogen, aspartate&#xD;
           transaminases (AST), alanine transaminase (ALT), alkaline phosphatase, total and direct&#xD;
           bilirubin, sodium, potassium, chloride, calcium, magnesium, total protein, and albumin.&#xD;
&#xD;
      g. Record results of sterile body fluid cultures (blood, urine, CSF, peritoneal fluid)&#xD;
      obtained as standard clinical care in the 72 hours prior to study drug administration. Record&#xD;
      urine cultures only if obtained by sterile catheterization or suprapubic aspiration.&#xD;
&#xD;
      h. Document concomitant medications in the 72 hours prior to study drug administration.&#xD;
&#xD;
      Procedures During Study Drug Administration (Study Days 1-2)&#xD;
&#xD;
      a. Record study drug timing of infusion before the PK samples are obtained - this includes&#xD;
      start/stop times of infusion and amount given b. Assess and record AEs from the time of the&#xD;
      first dose of study drug. c. Assess and record SAEs from the time of the first dose of study&#xD;
      drug. d. Record all concomitant antimicrobials and vasopressors administered e. Collect blood&#xD;
      for PK analysis (Appendix 2) f. Record result for clinical laboratory assessments obtained&#xD;
      per local standard of care one time daily while on study drug.&#xD;
&#xD;
        1. Hematology assays will include: hematocrit, hemoglobin, white blood cell count with&#xD;
           differential, and platelet count.&#xD;
&#xD;
        2. Serum chemistry will include glucose, creatinine, blood urea nitrogen, aspartate&#xD;
           transaminases (AST), alanine transaminase (ALT), alkaline phosphatase, total and direct&#xD;
           bilirubin, sodium, potassium, chloride, calcium, magnesium, total protein, and albumin.&#xD;
&#xD;
      g. Record the results of cultures from sterile body fluids (blood, urine, CSF, peritoneal&#xD;
      fluid, or any other sterile body fluid) as obtained per standard of care. Record urine&#xD;
      cultures only if obtained by sterile catheterization or suprapubic aspiration.&#xD;
&#xD;
      Procedures following Study Drug Administration&#xD;
&#xD;
        1. Assess and record adverse events (AEs) for 72 hours following the last dose of study&#xD;
           drug&#xD;
&#xD;
        2. Assess and record serious adverse events (SAEs) for 7 days following the last dose of&#xD;
           study drug&#xD;
&#xD;
      Safety&#xD;
&#xD;
      Adverse Events&#xD;
&#xD;
      Reporting period AEs will be recorded from the time of informed consent until 72 hours&#xD;
      following the last dose of study drug for non SAEs and until 7 days after the last dose of&#xD;
      study drug for SAEs. Any AE that occurs between the time informed consent is obtained and the&#xD;
      initial dose of study, that is considered related to a protocol specified procedure, must be&#xD;
      reported.&#xD;
&#xD;
      Procedures for assessing, recording and reporting AEs Throughout the duration of the study,&#xD;
      the investigator will closely monitor each subject for clinical evidence of drug intolerance&#xD;
      and monitor all clinically obtained laboratory values for laboratory evidence of AEs. AEs not&#xD;
      explained by the infant's underlying illness which occur during the course of the study will&#xD;
      be reported in detail on the appropriate CRFs and followed until resolution or until it&#xD;
      becomes stable. All SAEs will be reported to study's medical monitor within 24 hours.&#xD;
&#xD;
      The description of the AE will include description of event, start date, stop date,&#xD;
      intensity, if it was serious, and relationship to the study drug. The investigator must&#xD;
      verify this information.&#xD;
&#xD;
      The Investigator is responsible for assessing relationship to study medication.&#xD;
&#xD;
      Blood Volume for PK and Safety Laboratory Tests&#xD;
&#xD;
      Blood sample volume will be minimized by:&#xD;
&#xD;
      Hematology and chemistry laboratory measures will be recorded from laboratories drawn as&#xD;
      standard of care and will not be drawn strictly for purpose of this study.&#xD;
&#xD;
      A limited PK sampling scheme will be employed such that no more than a total of 0.8 mL of&#xD;
      blood (4 samples) is obtained from each subject for PK analysis.&#xD;
&#xD;
      Statistical Methods&#xD;
&#xD;
      Definitions and Populations for Analysis All infants who receive piperacillin-tazobactam will&#xD;
      be analyzed. These infants will comprise the population for the safety analysis, and if any&#xD;
      PK samples are obtained, their blood will be evaluated in the PK analysis.&#xD;
&#xD;
      Demographics Descriptive statistics such as number of observations, mean, median, 95%&#xD;
      confidence interval, standard deviation, standard error, minimum, and maximum will be&#xD;
      presented by group for continuous variables (such as age, weight, etc). Other descriptive&#xD;
      statistics such as counts, proportions, and/or percentages will be presented by dosage group&#xD;
      to summarize discrete variables (such as race, sex, success rates, mortality rates, etc.) The&#xD;
      number of infants completed, and discontinued early from study, and the reasons for&#xD;
      discontinuation, will be summarized. Demographic and baseline characteristics will be&#xD;
      summarized by group. Variables include race, age, sex, and selected clinical variables&#xD;
      recorded prior to initiation of study drug.&#xD;
&#xD;
      7.4 Pharmacokinetics&#xD;
&#xD;
      The following PK parameters will be estimated:&#xD;
&#xD;
        1. Systemic clearance (CL)&#xD;
&#xD;
        2. Volume of distribution (Vd)&#xD;
&#xD;
        3. maximum concentration (Cmax), time at maximum concentration (Tmax), area under the curve&#xD;
           (AUC0-Τ), Ke and half-life (t1/2)&#xD;
&#xD;
        4. CSF/plasma piperacillin-tazobactam concentration ratio&#xD;
&#xD;
        5. Endotracheal aspirate/plasma piperacillin-tazobactam concentration ratio&#xD;
&#xD;
        6. Saliva/plasma piperacillin-tazobactam concentration ratio&#xD;
&#xD;
        7. Urine/plasma piperacillin-tazobactam concentration ratio&#xD;
&#xD;
      The PK parameters and MIC will be used to estimate pharmacodynamic parameters of exposure&#xD;
      (time above MIC). Using sparse sampling PK analysis, parameters (clearance, Vd) will be&#xD;
      estimated for the following each of the cohorts. The plasma concentrations-time profiles of&#xD;
      piperacillin-tazobactam will be presented in tabular and graphical form by subject, age&#xD;
      cohort, and dosage level. The relationship between plasma concentrations and/or PK parameters&#xD;
      with demographic factors (weight, gestational age, postnatal age), disease severity, toxicity&#xD;
      and co-administered medications will be investigated. Analysis of potential relationships&#xD;
      between drug and exposure in subjects and the resulting efficacy and/or safety response will&#xD;
      be conducted.&#xD;
&#xD;
      Sample Size The sample size is designed to assess multiple dose PK of piperacillin-tazobactam&#xD;
      in young infants. At least 4 infants will be enrolled in each of the GA/PNA cohorts. Infants&#xD;
      will be enrolled to ensure that at least 4 infants with ≥3 evaluable PK samples are enrolled&#xD;
      in each cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Piperacillin Pharmacokinetics (PK)</measure>
    <time_frame>2-3 days after infant receives 1st drug dosing</time_frame>
    <description>To study how Piperacillin is metabolized in the body by measuring the drug concentration in plasma samples collected at different time points during the study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open label -- 6 interval doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin-tazobactam</intervention_name>
    <description>6 doses intravenously at the following doses:&#xD;
Infants &lt;32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6&#xD;
Infants ≥32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q6&#xD;
≥ 14 days PNA 100 mg/kg Q6</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written permission from parent or legal guardian&#xD;
&#xD;
          2. &lt; 61 days of age&#xD;
&#xD;
          3. Likely to survive beyond the first 48 hours after enrollment&#xD;
&#xD;
          4. Sufficient intravascular access (either peripheral or central) to receive study drug.&#xD;
&#xD;
        AND ONE OF THE FOLLOWING&#xD;
&#xD;
          1. Suspected systemic infection&#xD;
&#xD;
          2. Receiving piperacillin-tazobactam as part of standard of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergic reactions to any penicillin, cephalosporins, or beta-lactamase&#xD;
             inhibitors&#xD;
&#xD;
          2. Urine output &lt; 0.5 mL/hr/kg over the prior 24 hours&#xD;
&#xD;
          3. Serum creatinine &gt; 1.2 mg/dL&#xD;
&#xD;
          4. Any condition which would make the subject or the caregiver, in the opinion of the&#xD;
             investigator, unsuitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip B. Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Universtity Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <results_first_submitted>November 25, 2012</results_first_submitted>
  <results_first_submitted_qc>May 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2013</results_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Phillip Brian Smith</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>presumed sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants recruited from intensive care nurseries.First subject was recruited/enrolled on 1/29/2010. Last subject was enrolled on 7/29/2010. A total of 32 subjects were enrolled at 4 participant sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GA of 32 Wks, PNA of 14 Days</title>
          <description>Open label -- 6 interval doses&#xD;
piperacillin-tazobactam : 6 doses intravenously at the following doses:&#xD;
Infants &lt;32 weeks gestation at birth &lt; 14 days postnatal age (PNA) 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6&#xD;
Infants ≥32 weeks gestation (GA) at birth &lt; 14 days PNA 100 mg/kg Q6&#xD;
≥ 14 days PNA 100 mg/kg Q6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GA of 32 Wks, PNA of 14 Days</title>
          <description>Open label -- 6 interval doses&#xD;
piperacillin-tazobactam : 6 doses intravenously at the following doses:&#xD;
Infants &lt;32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6&#xD;
Infants ≥32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q6&#xD;
≥ 14 days PNA 100 mg/kg Q6</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Piperacillin Pharmacokinetics (PK)</title>
        <description>To study how Piperacillin is metabolized in the body by measuring the drug concentration in plasma samples collected at different time points during the study</description>
        <time_frame>2-3 days after infant receives 1st drug dosing</time_frame>
        <population>All 32 subjects that were enrolled during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>PK Analysis Cohort - Piperacillin Plasma Clearance</title>
            <description>Open label -- 6 interval doses&#xD;
piperacillin-tazobactam : 6 doses intravenously at the following doses:&#xD;
Infants &lt;32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6&#xD;
Infants ≥32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q6&#xD;
≥ 14 days PNA 100 mg/kg Q6</description>
          </group>
        </group_list>
        <measure>
          <title>Piperacillin Pharmacokinetics (PK)</title>
          <description>To study how Piperacillin is metabolized in the body by measuring the drug concentration in plasma samples collected at different time points during the study</description>
          <population>All 32 subjects that were enrolled during the study.</population>
          <units>L/hr/kg</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0799" lower_limit="0.0677" upper_limit="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>AEs/SAEs were collected. None SAE was observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>GA of 32 Wks, PNA of 14 Days</title>
          <description>Open label -- 6 interval doses&#xD;
piperacillin-tazobactam : 6 doses intravenously at the following doses:&#xD;
Infants &lt;32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6&#xD;
Infants ≥32 weeks gestation at birth &lt; 14 days PNA 100 mg/kg Q6&#xD;
≥ 14 days PNA 100 mg/kg Q6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Smith, MD. MPH</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-8951</phone>
      <email>brian.smith@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

